Substance/medication-induced anxiety disorder (SMIAD) is the diagnosis applied when prominent panic or anxiety symptoms develop during or soon after intoxication, withdrawal, or therapeutic exposure to a substance capable of producing those symptoms, and when the temporal and pharmacologic relationship is strong enough to make the substance the most likely cause. It sits in the DSM-5-TR Anxiety Disorders chapter alongside primary anxiety syndromes, but the diagnostic logic is fundamentally different: the clinician must establish that the symptoms are not better explained by an independent anxiety disorder that happens to coexist with substance use.¹ The clinical stakes are high — caffeine, stimulants, cannabis withdrawal, alcohol withdrawal, sedative-hypnotic withdrawal, corticosteroids, and beta-agonists are common culprits, and missing the etiologic link leads to escalating benzodiazepine or SSRI prescribing for a condition that resolves with substance removal. Most cases remit within days to weeks once the offending agent is removed or the withdrawal state resolves, though stimulant- and sedative-withdrawal anxiety can persist longer. The bedside priorities are a careful timeline, a urine drug screen when appropriate, and a deliberate watchful-waiting period before committing to long-term anxiolytic pharmacotherapy.

Population-level prevalence estimates are imprecise because SMIAD is under-recognized and frequently miscoded as a primary anxiety disorder. The disorder is best understood in terms of the populations and exposures in which it concentrates rather than as a single epidemiologic entity.

Prevalence and clinical context

• 12-month prevalence in community samples is low (well under 1%), but the diagnosis is substantially more common in addiction treatment settings, emergency departments, and consultation-liaison services.²
• Among individuals with a substance use disorder, anxiety symptoms attributable to the substance (rather than a co-occurring primary anxiety disorder) are estimated in the range of 20-40% during active use or withdrawal, depending on the substance and the assessment timing.^2-3
• Caffeine is the single most common pharmacologic cause of clinically significant anxiety in otherwise healthy adults, with risk rising at intakes above 400 mg/day and panic symptoms common above 600 mg/day.⁴

Demographic patterns

• Sex distribution tracks the underlying substance exposure rather than a sex-specific vulnerability — stimulant- and cannabis-related cases skew younger and male, while sedative-withdrawal and prescription-medication cases (corticosteroids, levothyroxine over-replacement, beta-agonists) skew older and more female.
• Age of onset is bimodal: adolescence and young adulthood for illicit-substance presentations, and middle to older age for iatrogenic presentations driven by polypharmacy.

Comorbidity

• Co-occurring substance use disorder is by definition near-universal in the substance-induced subtype.
• Primary anxiety disorders coexist in a substantial minority and complicate diagnosis; longitudinal follow-up after substance abstinence is the cleanest way to disentangle the two.³
• Mood disorders, particularly major depressive disorder and bipolar II, are frequent companions, especially in stimulant and alcohol-related presentations.

Substance-induced anxiety reflects the direct pharmacology of the offending agent on circuits that mediate fear, arousal, and autonomic tone. The mechanisms differ by substance class but converge on a small set of final common pathways.

Neurotransmitter and circuit mechanisms

• Sympathomimetic activation: stimulants (cocaine, amphetamines, methylphenidate), caffeine, and beta-agonists drive monoaminergic and adenosine-receptor effects that increase locus coeruleus firing and noradrenergic output to the Amygdala and prefrontal cortex.⁵
• GABAergic withdrawal: abrupt cessation of alcohol or sedative-hypnotics (benzodiazepines, barbiturates, gabapentinoids in chronic high-dose use) removes tonic inhibition at GABA-A receptors, producing a hyperadrenergic and anxious state that can progress to seizures and delirium.⁶
• Serotonergic and cannabinoid effects: cannabis (especially high-THC products), hallucinogens, and MDMA produce acute anxiety and panic through 5-HT2A and CB1 receptor activity, with the Default Mode Network implicated in the depersonalization and derealization that often accompany these reactions.⁷
• HPA-axis and glucocorticoid effects: corticosteroids and Cushing-spectrum endogenous excess produce anxiety through direct glucocorticoid receptor effects in limbic structures, often with insomnia and irritability.
• Thyroid hormone excess: exogenous levothyroxine over-replacement or factitious use mimics generalized anxiety and panic via beta-adrenergic upregulation.

Genetic and host factors

• Individual susceptibility varies with cytochrome P450 polymorphisms (notably CYP1A2 for caffeine), baseline anxiety trait, and prior panic history.⁴
• A personal or family history of panic disorder lowers the threshold for substance-provoked panic, particularly with cannabis and stimulants.

The DSM-5-TR criteria require panic or anxiety symptoms that are temporally and pharmacologically linked to a substance, and that are not better explained by an independent anxiety disorder.¹

Core criteria

• Prominent panic attacks or anxiety symptoms predominate the clinical picture.
• Evidence from history, examination, or laboratory findings supports both of the following:
  • The symptoms developed during or soon after intoxication or withdrawal from a substance, or after exposure to or withdrawal from a medication.
  • The implicated substance or medication is capable of producing the symptoms.
• The disturbance is not better explained by a primary anxiety disorder. Evidence pointing to an independent disorder includes symptoms preceding the substance use, persistence beyond about one month after acute withdrawal or cessation of exposure, or a clearly disproportionate symptom burden.
• Symptoms do not occur exclusively during the course of a delirium.
• Symptoms cause clinically significant distress or impairment.

Specifiers

• With onset during intoxication: criteria for intoxication with the substance are met and symptoms develop during intoxication.
• With onset during withdrawal: criteria for withdrawal are met and symptoms develop during or shortly after withdrawal.
• With onset after medication use: symptoms appear at initiation of, during use of, or following a change in or discontinuation of a medication.

ICD-11 differences

• ICD-11 places substance-induced anxiety within each substance-specific disorder block (e.g., 6C40.4 for alcohol-induced anxiety disorder), rather than aggregating them in the anxiety chapter as DSM-5-TR does.⁸
• ICD-11 generally requires that symptoms are out of proportion to expected intoxication or withdrawal effects, framing the diagnosis slightly more conservatively than DSM-5-TR.

Presentation depends on which substance is in play and on whether the patient is intoxicated, withdrawing, or stably exposed to a culprit medication. The pattern of symptoms, the timeline, and the autonomic signature together point toward the responsible agent.

Intoxication-pattern anxiety

• Stimulants and caffeine: panic attacks, restlessness, tremor, tachycardia, sweating, mydriasis, and hypervigilance — often peaking within hours of ingestion.
• Cannabis: acute panic, depersonalization, paranoia, and a sense of impending doom, more common with high-THC products and in cannabis-naive users.⁷
• Hallucinogens and MDMA: panic mixed with perceptual disturbance, autonomic surge, and hyperthermia.

Withdrawal-pattern anxiety

• Alcohol withdrawal: anxiety begins 6-24 hours after the last drink, with tremor, sweating, tachycardia, and insomnia; severe cases progress to Delirium Tremens.⁶
• Sedative-hypnotic withdrawal: a similar autonomic and anxious picture, with onset depending on half-life — within 1-2 days for short-acting agents (alprazolam, lorazepam) and up to a week for long-acting agents (diazepam, clonazepam).
• Opioid withdrawal: anxiety and dysphoria are prominent and often the most distressing features, alongside lacrimation, rhinorrhea, piloerection, and gastrointestinal symptoms.
• Cannabis withdrawal: irritability, anxiety, sleep disturbance, and decreased appetite, peaking in the first week of abstinence.

Medication-induced anxiety

• Corticosteroids: anxiety, agitation, insomnia, and at higher doses frank mood and psychotic symptoms; risk rises sharply above prednisone equivalents of 40 mg/day.
• Beta-agonists (albuterol, salmeterol, terbutaline): tremor, palpitations, and anxiety, especially with nebulized or systemic dosing.
• Levothyroxine over-replacement: a chronic low-grade anxiety with palpitations, heat intolerance, and weight loss; suppressed TSH confirms.
• Dopaminergic agents (levodopa, pramipexole, ropinirole): anxiety, impulsivity, and at higher doses psychosis.
• Antidepressant initiation: transient activation anxiety in the first 1-2 weeks of SSRI or SNRI therapy, particularly with fluoxetine and sertraline.
• Decongestants and herbal stimulants: pseudoephedrine, ephedra, yohimbine, and synephrine-containing supplements are easy to miss without explicit questioning.

Course and red flags

• Symptoms that resolve within hours to days of substance removal (intoxication) or within 1-4 weeks of completed withdrawal point strongly to a substance-induced cause.¹
• New-onset panic in a patient over 40 with no prior anxiety history should prompt a careful medication and substance review before a primary anxiety diagnosis is made.
• Anxiety with focal neurologic findings, chest pain, or marked autonomic instability requires medical workup before psychiatric attribution.

The differential turns on whether anxiety is the substance's effect, the substance's withdrawal, an independent psychiatric disorder, or a medical mimic. Several entities recur and deserve specific differentiation.

Primary anxiety disorders

• Panic disorder, generalized anxiety disorder, and social anxiety disorder all predate substance exposure when independent. A clean pre-substance history of identical symptoms argues against the substance-induced diagnosis.
• Anxiety persisting more than about a month after the substance has cleared favors a primary anxiety disorder.

Other substance-related diagnoses

• Substance intoxication or withdrawal alone (without prominent anxiety predominating) is coded as the intoxication or withdrawal syndrome, not as SMIAD.
• Substance/medication-induced depressive, psychotic, or sleep disorders may co-occur and should be diagnosed separately when each predominates.

Medical mimics

• Hyperthyroidism: weight loss, heat intolerance, tremor, tachycardia, and a suppressed TSH.
• Pheochromocytoma: paroxysmal hypertension, headache, sweating, and palpitations — rare but classically tested.
• Cardiac arrhythmias and ischemia: especially in older patients presenting with first-episode panic.
• Hypoglycemia, hypoxia, pulmonary embolism, and asthma exacerbations: episodic dyspnea and tachycardia mimic panic.
• Complex partial seizures and vestibular disorders: episodic fear, derealization, and dizziness without the classic crescendo of panic.

Delirium

• Anxiety-predominant delirium (e.g., post-anesthesia, ICU, sedative withdrawal) is common but is coded as delirium, not SMIAD, when fluctuating attention and consciousness are present.

Assessment combines a structured substance and medication history, targeted physical examination, and a small focused laboratory workup. The goal is to confirm exposure, exclude medical mimics, and establish a baseline against which to judge resolution.

History essentials

• Detailed substance use history including alcohol, tobacco, cannabis, stimulants, opioids, sedatives, hallucinogens, inhalants, and synthetic cannabinoids.
• Caffeine intake quantified in mg/day across coffee, tea, energy drinks, pre-workout supplements, and combination analgesics.
• A complete medication list including over-the-counter agents, herbal products, weight-loss supplements, and recent dose changes.
• Timeline anchored to symptom onset: what was started, stopped, or escalated in the preceding days to weeks.
• Personal and family history of anxiety, panic, mood, and psychotic disorders.

Physical examination

• Vital signs (looking for tachycardia, hypertension, fever, hyperventilation).
• Pupils, tremor, sweating, reflexes, and skin findings (track marks, stigmata of liver disease).
• Thyroid examination and cardiopulmonary auscultation.

Validated rating scales

• GAD-7 for generalized anxiety severity and longitudinal tracking.
• PDSS (Panic Disorder Severity Scale) when panic predominates.
• CIWA-Ar for alcohol withdrawal severity.
• COWS (Clinical Opiate Withdrawal Scale) for opioid withdrawal.
• AUDIT and DAST for screening underlying substance use disorders.

Laboratory and imaging

• Urine drug screen with awareness of false negatives for synthetic cannabinoids, novel stimulants, and many benzodiazepines (clonazepam, lorazepam are often missed on standard immunoassays).
• Blood alcohol level when intoxication is plausible.
• TSH and free T4 in any new anxiety presentation, particularly in adults over 40.
• Basic metabolic panel, calcium, magnesium, and a CBC.
• EKG for first-episode panic in patients over 40, with risk factors, or with chest pain.
• Imaging (CT or MRI) is not routine and should be reserved for focal neurologic findings, atypical features, or first-episode psychosis-spectrum presentations.

What not to order

• Routine neuroimaging, EEG, and extensive autoimmune panels in a typical SMIAD presentation add cost without changing management.

The cornerstone of management is removing the offending agent or supporting the patient through withdrawal. Pharmacologic treatment of the anxiety itself is a bridge, not a destination, and should be reassessed once the substance question is settled.

Pharmacotherapy

• Strong evidence supports benzodiazepine taper protocols (chlordiazepoxide, diazepam, lorazepam) for alcohol and sedative-hypnotic withdrawal anxiety, dosed by symptom severity using CIWA-Ar-guided protocols.^6,9
• Evidence suggests alpha-2 agonists (clonidine, lofexidine) and supportive care reduce autonomic and anxiety symptoms of opioid withdrawal; buprenorphine or methadone induction is recommended when opioid use disorder is present.¹⁰
• Limited evidence suggests beta-blockers (propranolol 10-40 mg as needed) reduce peripheral autonomic symptoms in stimulant- and caffeine-related anxiety, without reliable effect on the core fear experience.
• For medication-induced anxiety, dose reduction or substitution of the offending agent is the definitive intervention; a short course of a low-dose benzodiazepine may be reasonable while corticosteroid tapers are completed, though high-quality evidence is lacking.
• SSRIs and SNRIs are not first-line for the substance-induced syndrome itself. They are appropriate when a primary anxiety disorder is identified after the substance is removed and symptoms persist.

Psychotherapy

• Evidence suggests Cognitive Behavioral Therapy for anxiety reduces symptom burden during recovery from substance use, particularly when integrated with substance use disorder treatment.¹¹
• Motivational interviewing supports engagement with substance reduction or abstinence, which is the etiologic intervention.
• Psychoeducation about the substance-anxiety link is itself therapeutic — patients who understand that their panic is caffeine-driven often reduce intake without further intervention.

Neuromodulation

• Neuromodulation has no established role in substance-induced anxiety per se. ECT and rTMS are not indicated unless a comorbid primary mood or anxiety disorder warrants them on its own merits.

Adjunctive

• Sleep stabilization, caffeine elimination, structured exercise, and avoidance of triggering supplements (pre-workouts, weight-loss products containing synephrine or yohimbine) are practical and underused.
• Treatment of co-occurring substance use disorder is essential — naltrexone or acamprosate for alcohol use disorder, buprenorphine or methadone for opioid use disorder, and contingency management for stimulant use disorder.¹²

The dominant harms in this disorder come from misdiagnosis and from the medications used to treat it, not from the syndrome itself. The literature is also constrained by small samples, short follow-up, and substantial overlap with primary anxiety populations.

• Common harms: oversedation and dependence from prolonged benzodiazepine use; missed primary anxiety disorder when symptoms are reflexively attributed to substance use; missed medical mimic (hyperthyroidism, pheochromocytoma, arrhythmia) when substance attribution is premature.
• Serious or rare harms: respiratory depression and death when benzodiazepines are combined with active opioid or alcohol use; seizures and delirium when sedative-hypnotic withdrawal is undertreated; serotonin syndrome when MDMA or stimulant exposure is layered on existing serotonergic medication.
• Monitoring and discontinuation: SSRI/SNRI discontinuation produces its own anxiety syndrome that mimics relapse; benzodiazepine tapers must be slow (often 10-25% per 1-2 weeks) to avoid rebound anxiety and seizures.
• Evidence limitations: most data are observational or extrapolated from primary anxiety and substance use disorder trials; few RCTs target substance-induced anxiety specifically; follow-up beyond 12 weeks is sparse; populations with polysubstance use, severe medical comorbidity, and pregnancy are underrepresented.

Substance and medication exposures vary across the lifespan and across medical contexts, and the differential weighting of culprits shifts accordingly.

Pediatric and adolescent

• Energy drinks, pre-workout supplements, and ADHD stimulants (prescribed and diverted) are common precipitants.
• Cannabis-induced panic in adolescents is a frequent ED presentation, often with first-time use of high-THC concentrates or edibles where dose is harder to titrate.
• Albuterol overuse in poorly controlled asthma is an underrecognized contributor.

Geriatric

• Polypharmacy is the dominant risk: corticosteroids, levothyroxine over-replacement, beta-agonists, anticholinergic load, and recent antibiotic courses (fluoroquinolones, clarithromycin) all warrant review.
• Alcohol use disorder is underdiagnosed in older adults; sedative-hypnotic dependence accumulated over decades is common.
• Withdrawal syndromes are more dangerous in this population because of cardiovascular and cognitive reserve.

Perinatal

• New-onset anxiety in pregnancy or postpartum should prompt a careful review of thyroid status, caffeine intake, and any recent substance use.
• Treatment decisions balance fetal and infant exposure against maternal symptom burden; sertraline is generally preferred among SSRIs in lactation when pharmacotherapy is required.¹³

Comorbid medical illness

• Asthma and COPD: beta-agonist load and corticosteroid bursts are common drivers.
• Cardiac disease: arrhythmia and ischemia must be excluded before substance attribution; many cardiovascular medications have anxiety as an adverse effect.
• Endocrine: hyperthyroidism, Cushing syndrome, and pheochromocytoma all mimic substance-induced anxiety.

Comorbid substance use disorder

• Treatment of the underlying SUD is the etiologic intervention; failure to treat the SUD predicts symptom recurrence regardless of anxiolytic strategy.
• Polysubstance use complicates timeline-based diagnosis and often requires a period of supervised abstinence to clarify.

Cultural considerations

• Khat (Catha edulis), kratom, areca nut, and culturally specific stimulant beverages are easy to miss without explicit questioning in patients from regions where these are common.

Prognosis is generally favorable when the substance link is identified and acted on. Persistence beyond expected timelines should prompt re-evaluation rather than escalation.

• Most intoxication-pattern symptoms resolve within hours to a few days of substance clearance.
• Withdrawal-pattern anxiety typically resolves within 1-4 weeks of completed acute withdrawal, though stimulant- and sedative-withdrawal anxiety can persist for several months in subsets of patients (sometimes termed protracted withdrawal).⁶
• Medication-induced anxiety resolves on a timeline tied to the half-life of the offending agent and to the steroid taper schedule when corticosteroids are involved.
• Persistence beyond about one month after the substance has cleared and acute withdrawal has resolved should raise concern for an unmasked or coexisting primary anxiety disorder.¹
• Long-term outcome depends predominantly on the trajectory of the underlying substance use disorder; sustained abstinence is associated with substantial reduction in anxiety symptoms.³
• Suicide risk is elevated in the broader substance use disorder population and warrants ongoing assessment, particularly during withdrawal and early abstinence.

Severe presentations of substance-induced anxiety overlap with medical emergencies and require parallel medical and psychiatric assessment.

Hospitalization criteria

• Severe alcohol or sedative-hypnotic withdrawal (CIWA-Ar above 15, history of withdrawal seizures or delirium tremens, significant comorbidity).
• Sympathomimetic toxicity with hyperthermia, hypertensive emergency, or evidence of end-organ injury.
• Inability to maintain hydration, safety, or medication adherence outpatient.
• Active suicidal ideation with intent or plan, particularly in the context of intoxication or early withdrawal.

Suicide risk markers

• Active substance intoxication, particularly alcohol, lowers the threshold for impulsive self-harm.
• Early abstinence, anhedonia, and protracted withdrawal anxiety are higher-risk windows.
• Access to lethal means, prior attempts, and recent loss compound risk.

Agitation management

• For sympathomimetic-driven agitation, benzodiazepines (lorazepam, diazepam) are the mainstay; antipsychotics are added when agitation is severe or psychotic features are present.
• Avoid physical restraint when possible; cooling, hydration, and a low-stimulation environment are first-line for stimulant toxicity.

Several debates remain unresolved and shape how the diagnosis is applied at the bedside.

• Threshold for attribution: how strong must the temporal and pharmacologic link be before clinicians attribute anxiety to a substance? DSM-5-TR and ICD-11 differ in their thresholds, with ICD-11 framed slightly more conservatively.⁸
• Cannabis-induced anxiety: rising potency of contemporary cannabis products has increased ED presentations, but population-level estimates and the boundary between acute intoxication anxiety and a more persistent cannabis-induced anxiety disorder remain contested.⁷
• SSRI activation: whether early-treatment anxiety with SSRIs and SNRIs constitutes a true substance/medication-induced anxiety disorder or a transient adverse effect is unsettled, and labeling practices vary across guidelines.
• Protracted stimulant and sedative withdrawal: the existence and duration of post-acute withdrawal anxiety is recognized clinically but not consistently coded; some experts argue it should remain a substance-induced diagnosis well beyond one month, while others reclassify persistent symptoms as a primary anxiety disorder.
• Caffeine: caffeine-induced anxiety disorder is well-characterized, but caffeine use disorder itself remains a condition for further study in DSM-5-TR rather than a recognized diagnosis, leaving the management framework less codified than for other substances.^1,4

• Substance/medication-induced anxiety disorder requires temporal and pharmacologic linkage to a substance and that symptoms are not better explained by a primary anxiety disorder.
• Symptoms persisting more than about one month after the substance has cleared and acute withdrawal has resolved should prompt reconsideration of a primary anxiety disorder.
• Caffeine intake above 400 mg/day raises anxiety risk; panic symptoms become common above 600 mg/day.
• Alcohol withdrawal anxiety begins 6-24 hours after the last drink and is managed with symptom-triggered benzodiazepines using CIWA-Ar.
• Severe alcohol or sedative-hypnotic withdrawal can progress to seizures and delirium tremens; benzodiazepine taper is the standard of care.
• Opioid withdrawal anxiety responds to alpha-2 agonists (clonidine, lofexidine) and to opioid agonist treatment with buprenorphine or methadone.
• Corticosteroid-induced anxiety risk rises sharply above prednisone equivalents of 40 mg/day.
• Levothyroxine over-replacement produces a chronic anxiety picture with suppressed TSH; check TSH in any new anxiety presentation.
• Cannabis-induced panic is more common with high-THC products, edibles, and cannabis-naive users.
• Beta-agonists (albuterol, salmeterol) commonly produce tremor, palpitations, and anxiety, particularly with overuse.
• Pheochromocytoma classically presents with paroxysmal hypertension, headache, sweating, and palpitations and should be considered in atypical adult-onset panic.
• The diagnosis is not made when symptoms occur exclusively during a delirium.
• Pseudoephedrine, ephedra, yohimbine, and synephrine in supplements are common over-the-counter precipitants and require explicit questioning.
• Initiating long-term benzodiazepines in active alcohol or sedative use disorder carries substantial overdose and dependence risk and should be avoided.
• Sertraline is generally preferred among SSRIs in lactation when pharmacotherapy is required for persistent anxiety after substance clearance.

No external funding. No conflicts of interest declared. Peer-review status: pending.